Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Triple negative breast cancer

Share :

ECCO 15 - ESMO 34
Published: 5 Nov 2009
Views: 14058
Rating:
Save
Dr Susanne Briest - University of Leipzig, Germany
Dr Susanne Briest from the University of Leipzig, Germany, interviewed at ECCO 15 - ESMO 34, Berlin, Sept 2009. Features of triple negative breast cancer and various cancers within the triple negative grouping. PARP inhibitors. Grouping tumours by similarity to BRCA 1- 'BRCAness'. Multidisciplinary teams. Speaking to managing editor Prof Gordon McVie.

Related Videos

OncoAlert Round Up for August 25th - 31st, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Sep 2023
OncoAlert round up July 28th to August 3rd, 2023
Dr Gil Morgan - Executive Director, OncoAlert
OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )
4 Aug 2023
CDK4/6 inhibitors added to first line show no greater benefit when compared to...
Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2023
Prognostic value of HER2-low status in breast cancer: A systematic review and...
Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )
6 Jun 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
Loco-regional management after neoadjuvant chemotherapy
Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA
Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )
1 Feb 2023
Personalised risk-stratified breast cancer screening for BRCA germline...
Prof Banu Arun - MD Anderson Cancer Center, Houston, USA
Personalised risk-stratified breast cancer screening for BRCA germline mutations and other genes ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )
31 Jan 2023
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
Treatment decision guided by CTC count may improve long-term outcomes for mBC
Prof Jean-Yves Pierga - Institut Curie, Paris, France
Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )
9 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation